Drug prolongs IPF life expectancy: StudyTwo recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.
IPF drug to be tested with add-on therapyBoehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.
Top 3 new findings on nintedanib to treat IPFWhen two new treatments for idiopathic pulmonary fibrosis (IPF) were approved by FDA last year, there was not much data available on the drugs in patient populations.
Top 3 additions to IPF treatment guidelinesPulmonary fibrosis (PF) organizations and healthcare providers are lauding the update of the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis, which was last updated in 2011.
New study highlights benefits of nintedanib in IPF treatmentIIn a new long-term study, nintedanib (Ofev) improved forced vital capacity (FVC) and other idiopathic pulmonary fibrosis (IPF) symptoms. The findings were presented recently at the American Thoracic Society (ATS) 2015 International Conference in Denver.
FDA drug approvals - October 2014
FDA drug approvals - October 2014FDA actions in brief, fast-track designations, priority review.
Investigational TKI nintedanib slowed lung function loss in idiopathic pulmonary fibrosis
Investigational TKI nintedanib slowed lung function loss in idiopathic pulmonary fibrosisNintedanib, an investigational small molecule tyrosine kinase inhibitor (TKI), slowed lung function loss in patients with idiopathic pulmonary fibrosis (IPF), according to the results of 2 pivotal phase 3 trials presented at the American Thoracic Society International Conference in San Diego.